Alzamend Neuro 2020 Annual Report Form 1-K

Alzamend Neuro, Inc. is a Delaware biotech company developing immunotherapy treatments for Alzheimer's disease. The company filed its Form 1-K annual report for the fiscal year ended April 30, 2020, disclosing business operations and financial conditions. Unlike current FDA-approved Alzheimer's drugs that only address symptoms, Alzamend's approach targets the impaired immune system caused by the disease.